Trial Shows RA Can Be Stopped at Preclinical Stage
(MedPage Today) -- MILAN -- One year of treatment with abatacept (Orencia) kept "preclinical" rheumatoid arthritis (RA) from becoming clinical in most patients showing signs of imminent onset, a researcher reported here.
In a phase IIb randomized... (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - June 1, 2023 Category: Primary Care Source Type: news
New Tx Approach for Immunotherapy-Induced Myocarditis New Tx Approach for Immunotherapy-Induced Myocarditis
A novel combination of high-dose abatacept, ruxolitinib, and mechanical ventilation markedly improved immunotherapy-induced myocarditis survival over current guideline-recommended treatment.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 1, 2023 Category: Intensive Care Tags: Hematology-Oncology News Source Type: news
Anti-Inflammatory Agents May Have Role in COVID-19 Pneumonia
(MedPage Today) -- WASHINGTON -- Use of the anti-inflammatory agents infliximab (Remicade) and abatacept (Orencia) added to standard of care showed a hint of improvement in outcomes for patients hospitalized with COVID-19 pneumonia, according... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - October 25, 2022 Category: Infectious Diseases Source Type: news
Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
Possible Sex Differences Found in Early RA Drug Responses Possible Sex Differences Found in Early RA Drug Responses
In a rigorous analysis of sex differences in response to RA treatments, men had higher rates of remission than did women taking certolizumab pegol, abatacept, or conventional therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2022 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Researchers take aim at cancer drugs ’ toxic side effects
The patient was a success story, his advanced melanoma erased by a popular new cancer treatment. Known as immune checkpoint inhibitors, the drugs coax the immune system to seek and destroy cancer cells—and in this case, they “worked beautifully,” says Kerry Reynolds, an oncologist at Massachusetts General Hospital (MGH) who helped care for the man.
But about a month after an infusion, without a melanoma cell detectable in his body, the 64-year-old was admitted to the hospital, gravely ill. The drugs were sending his immune system into overdrive, wreaking havoc on his colon and nervous system.
Doctors strug...
Source: ScienceNOW - August 31, 2022 Category: Science Source Type: news
A Newly Published Network Meta-Analysis (NMA) Found TREMFYA ® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Conclusions (i.e., comparable) are based on an overlap of pairwise 95 percent credible intervals.1c. PASI 90 is defined as at least 90 percent improvement from baseline in the PASI score. The PASI score grades the amount of surface area on each body region that is covered by PsO plaques and the severity of plaques for their redness, thickness, and scaliness.13 PASI 90 was not a controlled endpoint in DISCOVER-1 or -2.8,9d. TREMFYA q4w dosing is not currently FDA-approved.2e. The PsA-modified vdH-S score combines erosion and joint space narrowing scores derived from radiographs of joints in body regions impacted by PsA.14 T...
Source: Johnson and Johnson - January 26, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves First Drug to Prevent GVHD in Cancer Patients FDA Approves First Drug to Prevent GVHD in Cancer Patients
Abatacept is the first drug approved for the prevention of acute graft-vs-host disease. Real-world evidence was part of the approval review.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
FDA approves abatacept for prophylaxis of acute graft versus host disease
On December 15, 2021, the Food and Drug Administration approved abatacept (Orencia, Bristol-Myers Squibb Company) for the prophylaxis of acute graft versus host disease (aGVHD) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 15, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves First Drug to Prevent Graft Versus Host Disease
SILVER SPRING, Md., Dec. 15, 2021 -- (Healthcare Sales & Marketing Network) -- Today, the U.S. Food and Drug Administration approved Orencia (abatacept) for the prophylaxis (prevention) of acute graft versus host disease (aGVHD), a condition that occurs w... Biopharmaceuticals, FDA Bristol Myers Squibb, Orencia, abatacept, Graft Versus Host (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 15, 2021 Category: Pharmaceuticals Source Type: news
U.S. Food and Drug Administration Approves Orencia (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)
PRINCETON, N.J.--(BUSINESS WIRE) December 15, 2021 -- Bristol Myers Squibb (NYSE:BMY) today announced that Orencia (abatacept) was approved by the U.S. Food and Drug Administration (FDA) for the prophylaxis, or prevention, of acute graft... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 15, 2021 Category: Drugs & Pharmacology Source Type: news
Abatacept Shows Signal to Delay Onset of Rheumatoid Arthritis Abatacept Shows Signal to Delay Onset of Rheumatoid Arthritis
Early results of a randomized clinical trial show that a 6-month course of abatacept may delay or prevent progression to rheumatoid arthritis.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - November 8, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Abatacept as Treatment for Diffuse Cutaneous Systemic Sclerosis Abatacept as Treatment for Diffuse Cutaneous Systemic Sclerosis
' Exploratory outcome measures during the open-label extension, including the composite ACR CRISS score, indicate that abatacept might promote overall global improvement in these participants. 'Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 29, 2020 Category: Dermatology Tags: Rheumatology News Source Type: news
Upadacitinib Tops Abatacept for RA Refractory to DMARDs
FRIDAY, Oct. 16, 2020 -- Upadacitinib is superior to abatacept for patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs (DMARDS), according to a study published online Oct. 15 in the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 16, 2020 Category: Pharmaceuticals Source Type: news
